Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.

Advertisements

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Phase 2 Treatment Naïve Lawitz E, et al. Lancet.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV-HIV Coinfection: HCV GT 1,2,3,4 PHOTON-2 Trial Phase 3 Molina JM, et al. IAC. 2014;

Hepatitis web study Hepatitis web study Ledipasvir + Sofosbuvir +/- Ribavirin in GT 1-3 ELECTRON 2 Phase 2 Treatment Naïve and Treatment Experienced Source:

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.

Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.

Hepatitis web study Hepatitis web study Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1 LONESTAR Trial Phase 2a Treatment Naïve and Treatment Experienced Source:

Hepatitis web study Hepatitis web study Sofosbuvir in HCV-HIV Coinfection & HCV GT 1,2,3 PHOTON-1 Trial Phase 3 Sulkowski MS, et al. JAMA. 2014;312:

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in Sofosbuvir-Experienced HCV GT1 Retreatment of Sofosbuvir Failures Phase 2 Treatment.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:

Hepatitis web study Hepatitis web study Sofosbuvir + Additional Agents ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

Hepatitis web study Hepatitis web study Sofosbuvir ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced Source: Gilead.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study Phase 3 Treatment-Naïve and Treatment-Experienced Nelson DR,

ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Genotype 1 NIAID/NIH Trial Phase 2, Treatment Naïve Treatment Naïve (unfavorable.

Hepatitis web study Hepatitis web study Sofosbuvir + RBV in Treatment-Naïve Genotypes 2,3 FISSION Trial* Phase 3 *Note: Published in NEJM in tandem with.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon+ Ribavirin in HCV-HIV GT 1-4 Phase 2 Rodriguez-Torres M, et al. J Acquir Immune Defic.

ARE PAN-GENOTYPIC THERAPIES READY FOR PRIME TIME? 3 Rd International HIV/Hepatitis Coinfection Meeting Durban SA Marina B. Klein, MD, MSc FRCP(C) Chronic.

Phase 3 Treatment Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced

Where Are We on the Path to Elimination of Chronic Hepatitis C?

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

Lesson 2: Special Considerations When Treating HIV/HCV Co-infection

Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3b Treatment-Naive

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 2 Treatment Naïve HIV Coinfection

HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.

Chronic Hepatitis C Virus Infection

Starting Strong: Initial Evaluation of the Patient With HCV

Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.

Case 53-year-old Black Man

HCV Care in Unique Patient Populations

Boceprevir in Treatment Naive SPRINT-2

Simeprevir in HIV Coinfection, GT-1 C212 Trial

Volume 69, Issue 4, Pages (October 2018)

Evaluation of the Patient With HCV Infection

Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.

Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.

Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I

HIV : New Agents, New Strategies

New Agents, New Regimens, New Strategies

Care of the Treatment-naive Patient With HCV/HIV Coinfection

Phase 3 Treatment-Naïve and Treatment-Experienced

Volume 59, Issue 4, Pages (October 2013)

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

Phase 2 Treatment Naïve and Treatment Experienced

Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3

Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and.

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

Hepatitis C: After the Diagnosis

A Guideline-Based Approach to HCV Care

Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Martina Gambato, Sabela Lens, Miquel Navasa, Xavier Forns

What Does the Future Hold and What Will It Mean for Patients?

Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)

Phase 3 Treatment-Naïve and Treatment-Experienced

Lesson 2: Special Considerations When Treating HIV/HCV Co-infection

Presentation transcript:

Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection

What's So "Special" About HCV-GT3 Infection?

Why Talk About HIV/HCV Coinfection?

ALLY-3 Study

ALLY-3 (cont) Daclatasvir + Sofosbuvir for 12 Weeks

ALLY-3+ Study Daclatasvir + Sofosbuvir + Ribavirin for 12 or 16 Weeks in Patients With Advanced Fibrosis or Cirrhosis Infected With HCV-GT3

ALLY-3+ Study (cont)

ALLY-3+ Study, cont

ASTRAL-3 Study Sofosbuvir/Velpatasvir

ASTRAL-3 Study (cont)

ASTRAL-3 Study (cont)

Real-World Data How Effective and Safe Are These Regimens in Clinical Practice?

French Multicenter Compassionate Use Program Interim Analysis

French Multicenter Compassionate Use Program Interim Analysis (cont)

European Multicenter Compassionate Use Program Interim Analysis

Back to the Ribavirin Question

ALLY-2 Daclatasvir/Sofosbuvir

Rethinking HIV/HCV Coinfection Are the Results Really As Good As for HCV Monoinfection?

GECCO: Real-World Data Sofosbuvir/Ledipasvir for 8 Weeks

Sofosbuvir/Daclatasvir In Patients With HIV/HCV Coinfection and Advanced Liver Disease A Real-World Trial

C-EDGE Grazoprevir/Elbasvir for 12 Weeks in HCV-GT1, 4, 6

C-EDGE, cont Evaluated Outcomes In Monoinfection and Coinfection

C-EDGE, cont Grazoprevir/Elbasvir for 12 Weeks in HCV-GT1, 4, 6

Summary

Abbreviations

Abbreviations (cont)